TKL Research is Building New Clinical Research Facility in Fair Lawn, NJ
TKL Research
, a full-service clinical research organization (
CRO
) with decades of experience in clinical trial management, is constructing a new clinical research facility in Fair Lawn, N.J., that will include a state-of-the-art, 30-bed, Phase 1 unit as well as multiple, outpatient clinical examination rooms.
The new facility, which will also give the company an expanded capability for conducting the full range of dermatological safety studies for which it has a particular expertise, will join three other TKL Research clinics in northern New Jersey as part of the company’s
Research Clinics
Division.
In addition to its leading dermatology capabilities, TKL Research has deep expertise in the areas of gastroenterology, respiratory, endocrinology and women’s health and significant experience in global clinical studies for pharmaceutical, medical device, nutritional and consumer health care companies. The company offers a full range of clinical trial management services, from strategy and protocol development to biostatistics, medical writing and regulatory submission.
“The Fair Lawn research facility will enable us to meet the increased demand for our services in the diseased-state populations for
Phase I clinical trials
in which we have strong patient recruitment expertise,” said TKL Research President and CEO Jon C. Anderson, Ph.D.
The new facility also complements the company’s Clinical Trials Division, based in Rochelle Park, NJ, which provides a full-service capability in the
clinical trial management
of international, multicenter Phase 2-4 studies.
Founded more than 60 years ago, TKL Research moved its CRO operations to Rochelle Park, NJ, in 2006, and expanded its European capabilities with clinical operations in Münster, Germany, in 2010.
“These moves, as well as the construction of our new facility in Fair Lawn, will help us continue to deliver exceptional services to our clients that give them a competitive edge and accelerated enrollment,” Anderson said. “We’re able to work with sponsors and investigators to accelerate enrollment of high-quality study participants, and, through our comprehensive management services, we deliver strong expertise in a comprehensive range of CRO services over a wide geographic area.”
The TKL Research Fair Lawn facility is expected to be operational early next year.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
